工程化益生菌用于肿瘤靶向联合化学免疫治疗
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
推进 CAR 免疫疗法在实体瘤中的应用：CAR-巨噬细胞和中性粒细胞
英文原题：Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils.
查看英文原题
Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
巨噬细胞和中性粒细胞是固有免疫系统的主要组成部分，在肿瘤微环境（TME）中促进血管生成、细胞外基质重塑、癌细胞增殖和转移方面发挥重要作用。在适当的刺激和修饰下，它们也可以被利用来介导细胞毒性肿瘤杀伤效应并协调有效的抗肿瘤免疫应答。因此，巨噬细胞和中性粒细胞在癌症免疫治疗中具有强大的潜力。在这篇综述中，我们简要概述了巨噬细胞或中性粒细胞在过继性细胞治疗中的应用，并重点关注了嵌合抗原受体（CAR）工程化的巨噬细胞（CAR-Ms）和中性粒细胞（CAR-Ns）。我们总结了CAR-Ms和CAR-Ns的构建策略、临床前和临床研究。最后，我们简要讨论了CAR-Ms和CAR-Ns的局限性和挑战，以及未来扩展其在治疗实体瘤中应用的研究方向。
展开英文摘要原文
Macrophages and neutrophils are the main components of the innate immune system and play important roles in promoting angiogenesis, extracellular matrix remodeling, cancer cell proliferation, and metastasis in the tumor microenvironment (TME). They can also be harnessed to mediate cytotoxic tumor killing effects and orchestrate effective anti-tumor immune responses with proper stimulation and modification.
Therefore, macrophages and neutrophils have strong potential in cancer immunotherapy. In this review, we briefly outlined the applications of macrophages or neutrophils in adoptive cell therapies, and focused on chimeric antigen receptor (CAR)-engineered macrophages (CAR-Ms) and neutrophils (CAR-Ns).
We summarized the construction strategies, the preclinical and clinical studies of CAR-Ms and CAR-Ns. In the end, we briefly discussed the limitations and challenges of CAR-Ms and CAR-Ns, as well as future research directions to extend their applications in treating solid tumors.
论文信息
- 作者
- Liang Y、Xu Q、Gao Q
- 单位
- Institute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2023
- 原文标识
- PubMed 38090576 · DOI 10.3389/fimmu.2023.1291619
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →